Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,235 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,156
Recruiting: 2,259
Ph III recruiting: 267
Growth YoY: +12.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 901–950 of 5,039 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05899049	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study	active not recruiting	Phase 3	251	Merck Sharp & Dohme LLCINDUSTRY	1	Aug 20, 2026	clinicaltrials
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT)	active not recruiting	Phase 2	36	Wake Forest University Health Sciences